NCT02866227View on ClinicalTrials.gov

TOL-463 Phase 2 Study for Vaginitis

PHASE2CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

July 15, 2016

Primary Completion Date

June 10, 2017

Study Completion Date

June 10, 2017

Conditions
Bacterial VaginosisVulvovaginal Candidiasis
Interventions
DRUG

TOL-463

TOL-463 vaginal gel

DRUG

TOL-463

TOL-463 vaginal insert

Trial Locations (2)

35294

University of Alabama at Birmingham School of Medicine- Infectious Disease, Birmingham

98104-2499

University of Washington - Harborview Medical Center - Center for AIDS and STD, Seattle

All Listed Sponsors
lead

Toltec Pharmaceuticals, LLC

INDUSTRY

NCT02866227 - TOL-463 Phase 2 Study for Vaginitis | Biotech Hunter | Biotech Hunter